Joaquin Martinez Arraras Caro, MD
Cardiovascular Disease · Amarillo, TXNPI 1598730269
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,984 of the $66,205 with a category attached, or 64.9%. 31 manufacturers reported payments, led by Amarin Pharma, Inc. at 40.9% of the total. Reporting peaked in 2019 at $40,996 and has fallen 93.1% since, to $2,817 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 546 payments — averaging $121.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$27K
- Amgen$15K
- Edwards Lifesciences$8K
- Pfizer$5K
- Abbott$4K
- Abiomed$2K
- plus $5K from 25 others
Across 112 payments — averaging $10,740 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$630K
- Novartis$305K
- Eli Lilly$143K
- Abbott$40K
- American Regent$40K
- Esperion Therapeutics, Inc.$28K
- plus $19K from 1 others
What the payments were for
- Consulting fees$5001%
- Speaking & faculty fees$42,98465%
- Travel & lodging$4,8627%
- Food & beverage$17,66127%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 41 | $27,088 |
| Amgen | 30 | $15,342 |
| Edwards Lifesciences | 224 | $8,000 |
| Pfizer | 16 | $5,365 |
| Abbott | 70 | $3,854 |
| Abiomed | 22 | $1,569 |
| Medtronic(2 entities) | 11 | $1,142 |
| E.r. Squibb & Sons, L.L.C. | 50 | $1,049 |
| Boston Scientific | 9 | $670 |
| Novartis | 20 | $441 |
| AstraZeneca | 12 | $322 |
| Shockwave Medical, Inc | 2 | $278 |
| Biotronik Inc. | 3 | $198 |
| Merck | 11 | $182 |
| Cordis US CORP. | 3 | $160 |
| Cvrx, Inc. | 1 | $103 |
| Novo Nordisk | 5 | $88 |
| Philips North America LLC | 1 | $83 |
| Boehringer Ingelheim | 2 | $37 |
| Galderma Laboratories, L.p. | 2 | $32 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $26 |
| BD | 1 | $23 |
| Penumbra, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Angiodynamics, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| CSL Behring | 1 | $16 |
| Biosense Webster, Inc. | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$26,313
- Repatha$14,934
- ELIQUIS$5,750
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,168
- Micra$836
- Impella$737
- XIENCE SIERRA$238
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$160
- Fortify Assura$148
- Rivacor 7 DR-T$141
- Acticor 7 VR-T DX$141
- Edora 8 DR-T$141
- BioMonitor$141
- Perclose ProGlide suture mediated closure system$126
- SYMPLICITY G3$124
- WATCHMAN Access System$119
- Supera peripheral stent system$119
- Vascular Lithotripsy$118
- Watchman$111
- JETi All In One Non-Sterile Kit$110
How this compares
$66,205 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 586 | $636,088 |
| EntrestoSacubitril/Valsartan | 189 | $253,113 |
| VascepaIcosapent Ethyl | 126 | $83,693 |
| FarxigaDapagliflozin Propanediol | 70 | $67,030 |
| VerquvoVericiguat | 33 | $61,045 |
| XareltoRivaroxaban | 28 | $38,898 |
| Repatha SureclickEvolocumab | 24 | $34,319 |
| BrilintaTicagrelor | 33 | $27,405 |
| Bisoprolol Fumarate | 593 | $16,905 |
| Icosapent Ethyl | 68 | $14,457 |
| Rosuvastatin Calcium | 937 | $13,481 |
| JardianceEmpagliflozin | 12 | $7,850 |
| Valsartan | 290 | $7,290 |
| ClopidogrelClopidogrel Bisulfate | 652 | $7,263 |
| LivaloPitavastatin Calcium | 11 | $5,958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $5,365 | $636,088586 claims |
| NovartisEntresto | $441 | $253,113189 claims |
| AstraZenecaFarxiga, Brilinta | $322 | $94,434103 claims |
| MerckVerquvo | $182 | $61,04533 claims |
| Johnson & JohnsonXarelto | $19 | $38,89828 claims |
| Boehringer IngelheimJardiance | $37 | $7,85012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Amarillo
- David BrabhamAmarillo$121K
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.